Tag Archives: TNF

October, 2017

23 October
Janssen’s Simponi Aria Receives FDA Approval for Psoriatic Arthritis and Ankylosing Spondylitis

Horsham, Pa., October 20, 2017 ― Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab), the only fully-human anti-tumor necrosis factor (TNF)-alpha therapy administered via a 30-minute infusion, for the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS). Today’s …
Share

23 November
AbbVie Terminates Development Program with Halozyme

SAN DIEGO, Nov. 21, 2016 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that AbbVie has discontinued a development program using the Halozyme ENHANZE™ platform technology and the tumor necrosis factor alpha (TNF-alpha) target following completion of a phase 1 study in which the target results were not achieved. …
Share

12 July
First Amgen Biosimilar Candidate & Adalimumab Biosimilar Candidate to be Reviewed by FDA Committee

THOUSAND OAKS, Calif., July 12, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the Company will discuss data supporting the ABP 501 Biologics License Application (BLA) with the U.S. Food and Drug Administration’s (FDA) Arthritis Advisory Committee. ABP 501 is a biosimilar candidate to Humira® (adalimumab), an anti-tumor necrosis factor-alpha (TNF-α) …
Share

18 March
Janssen’s Stelara Achieves Primary Endpoint in its Late-Stage Crohn’s Trial

AMSTERDAM, March 18, 2016 /PRNewswire/ — Phase 3 data presented at the 11th Congress of the European Crohn’s and Colitis Organisation (ECCO) showed that treatment with STELARA® (ustekinumab) induced clinical response and clinical remission in adult patients with moderate to severe Crohn’s disease who had previously failed or were intolerant to …
Share